Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement

• Kura Oncology revised executive employment agreements for CEO Troy Wilson on July 24, 2026, then for CCO Brian Powl, COO Kathleen Ford on July 27.
• Outside a corporate transaction window, severance shifts to 12 months base salary, up to 12 months COBRA premiums, option exercise period up to 12 months.
• Within 59 days before through 18 months post corporate transaction close, Wilson severance becomes 24 months salary, 200% target bonus, equity acceleration.
• In the same window, Powl and Ford severance becomes 18 months salary, 150% target bonus, equity acceleration.
• COBRA premium coverage extends to 24 months for Wilson, 18 months for Powl and Ford in corporate transaction-related terminations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-324202), on July 29, 2026, and is solely responsible for the information contained therein.